Avalo Therapeutics (AVTX) Other Non-Current Assets (2014 - 2026)
Avalo Therapeutics posted quarterly Other Non-Current Assets of $183000.0 for Q1 2026, up 39.69% year-on-year from $131000.0 in Q1 2025, and down 12.86% on a QoQ basis from $210000.0 in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Other Non-Current Assets data on file, last reported at $183000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 39.69% year-over-year to $183000.0; the trailing twelve-month figure through Mar 2026 stood at $183000.0 (up 39.69% YoY), and the FY2025 full-year result was $210000.0, up 60.31% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $183000.0, down from $210000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $227000.0 in Q1 2022 and bottomed at $131000.0 in Q4 2022.
- The 5-year median for Other Non-Current Assets is $131000.0 (2022), against an average of $162235.3.
- The widest annual swing landed in 2022, when Other Non-Current Assets slumped 42.29%; it then surged 60.31% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $131000.0 in 2022, then changed by 0.0% to $131000.0 in 2023, then changed by 0.0% to $131000.0 in 2024, then soared by 60.31% to $210000.0 in 2025, then decreased by 12.86% to $183000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $183000.0 (Q1 2026), $210000.0 (Q4 2025), and $210000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 183,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 183,000.00 |
| Dec 31, 2025 | 210,000.00 |
| Sep 30, 2025 | 210,000.00 |
| Jun 30, 2025 | 210,000.00 |
| Mar 31, 2025 | 131,000.00 |
| Dec 31, 2024 | 131,000.00 |
| Sep 30, 2024 | 131,000.00 |
| Jun 30, 2024 | 131,000.00 |
| Mar 31, 2024 | 131,000.00 |
| Dec 31, 2023 | 131,000.00 |
| Sep 30, 2023 | 131,000.00 |
| Jun 30, 2023 | 131,000.00 |
| Mar 31, 2023 | 131,000.00 |
| Dec 31, 2022 | 131,000.00 |
| Sep 30, 2022 | 181,000.00 |
| Jun 30, 2022 | 227,000.00 |
| Mar 31, 2022 | 227,000.00 |
| Dec 31, 2021 | 227,000.00 |
| Sep 30, 2021 | 227,000.00 |
| Jun 30, 2021 | 149,000.00 |
| Mar 31, 2021 | 149,000.00 |
| Sep 30, 2020 | 149,000.00 |
| Jun 30, 2020 | 180,000.00 |
| Mar 31, 2020 | 113,000.00 |
| Dec 31, 2019 | 101,945.00 |
| Sep 30, 2019 | 101,945.00 |
| Jun 30, 2019 | 152,162.00 |
| Mar 31, 2019 | 77,118.00 |
| Dec 31, 2018 | 81,725.00 |
| Sep 30, 2018 | 179,735.00 |
| Jun 30, 2018 | 175,042.00 |
| Mar 31, 2018 | 131,359.00 |
| Dec 31, 2017 | 100,000.00 |
| Sep 30, 2017 | 62,847.00 |
| Jun 30, 2017 | 62,841.00 |
| Mar 31, 2017 | 83,037.00 |
| Dec 31, 2016 | 62,828.00 |
| Sep 30, 2016 | 50,001.00 |
| Sep 30, 2015 | 117,165.00 |
| Dec 31, 2014 | 117,165.00 |